Abstracts tagged "autoantigens"

Abstract Number: 0773 • ACR Convergence 2020
The Anti-carbamylated Fibrinogen Response in Rheumatoid Arthritis Targets a Specific Epitope on the γ-chain and Is Associated with a More Active Disease
Pauline Brevet¹, Manuel Freret¹, Pascal Rottenberg², Clément Guillou³, Thierry Lequerre⁴, Pascal Cosette⁵, Olivier Boyer² and Olivier Vittecoq⁶, ¹Inserm U1234 and Rouen University , IRIB, Rouen, France ; Rouen University Hospital, Rheumatology Department, Rouen, France, Rouen, Haute-Normandie, France, ²Inserm U1234 and Rouen University , IRIB, Rouen, France ; Rouen University Hospital, Rheumatology Department, Rouen, France, Rouen, France, ³CNRS 6270, PISSARO, IRIB, Rouen, France ; Centre hospitalo-universitaire de Rouen, Immunology Laboratory, Rouen, France, Rouen, Haute-Normandie, France, ⁴Rheumatology, University Teaching Hospital, Rouen, France, ⁵CNRS 6270, PISSARO, IRIB, Rouen, France ; Centre hospitalo-universitaire de Rouen, Immunology Laboratory, Rouen, France, Rouen, France, ⁶University Hospital of Rouen, Rouen, France
Background/Purpose: Anti-carbamylated protein autoantibodies (anti-CarP Abs) of IgG and/or IgA isotype have potential diagnostic and prognostic value Carbamylated Fetal Calf Serum (FCS) is the substrate…
Abstract Number: 0775 • ACR Convergence 2020
T and B Cell Responses to Common Tenascin-C Peptides in RA
JING Song¹, Anja Schwenzer², Sara Turcinov³, Alicia Wong², Cliff Rims¹, Lorena Rodriguez Martinez², David Arribas-Layton⁴, Christina Gerstner⁵, Virginia Muir⁶, Jeffrey Carlin⁷, Kim Midwood², Vivianne Malmström⁸, Eddie James¹ and Jane Buckner¹, ¹Center for Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, ²Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ³Division of Rheumatology, Department of Medicine,Center for Molecular Medicine, Institutet, Stockholm, Sweden, ⁴Center for Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, ⁵Division of Rheumatology, Department of Medicine,Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden, ⁶Center for Systems Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁷Department of Rheumatology, Virginia Mason Medical Center, Seattle, WA, ⁸Karolinska Institutet, Stockholm, Stockholms Lan, Sweden
Background/Purpose: Although autoreactive CD4+ T cell and antibody responses against citrullinated antigens are known to contribute to loss of immune tolerance in rheumatoid arthritis (RA),…
Abstract Number: 0785 • ACR Convergence 2020
Identification of Recruited CCR2+ Inflammatory Monocytes in a Mouse Model of RA-associated Lung Disease with Potential Role for resolvin-D1 in Reducing Monocyte Inflammatory Responses
Austin Barry¹, Geoffrey Thiele¹, Ted Mikuls¹, Michael Duryee¹, Amy Nelson¹, Rohit Gaurav¹, Bryant England¹ and Jill Poole¹, ¹University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Patients with rheumatoid arthritis (RA) are at an increased risk for comorbid chronic lung disease, with premature mortality. Therapies for RA-associated lung disease are…
Abstract Number: 1078 • ACR Convergence 2020
Highly Reactive anti-Jo1 Autoantibodies to Distinct HisRS Variants and Domains Associate with Lung and Joint Involvement in Patients with Myositis
Antonella Notarnicola¹, Charlotta Preger², Susanna L. Lundström², Nuria Renard², Edvard Wigren², Eveline Van Gompel², Angeles S. Galindo-Feria², Helena Persson³, Maryam Fathi⁴, Johan Grunewald², Per-Johan Jakobsson², Susanne Gräslund², Ingrid Lundberg⁵ and Cátia Fernandes-Cerqueira², ¹Karolinska Institutet, Stockholm, Stockholms Lan, Sweden, ²Karolinska Institutet, stockholm, Sweden, ³Science for Life Laboratories, KTH, Stockholm, Sweden, ⁴Karolinska University Hospital, stockholm, Sweden, ⁵Division of Rheumatology, Department of Medicine, Karolinska Institutet,, Stockholm, Sweden
Background/Purpose: To address the reactivity and affinity against histidyl-transfer RNA synthetase (HisRS) autoantigen of anti-Jo1 autoantibodies from serum and bronchoalveolar lavage fluid (BALF) and associations…
Abstract Number: 1440 • ACR Convergence 2020
The Myeloperoxidase (MPO) Anti-Neutrophilic Cytoplasmic Antibody (ANCA) Binding Epitope, MPO447-459 Induces CD4 T-cell Proliferation in Patients with MPO-ANCA-associated Vasculitis
Matthew Terrill¹, Hendrik Nel², Yassmin Musthaffa³, Wong Richard⁴, Ross Francis⁵, David Johnson⁵, Greg Keir⁶, David Gillis⁷ and Ranjeny Thomas⁸, ¹University of Queensland Diamantina Institute and Princess Alexandra Hospital, Rheumatology Department, Brisbane- Australia, Moffat beach, Queensland, Australia, ²University of Queensland Diamantina Institute, Brisbane, Queensland, Australia, ³University of Queensland Diamantina Institute, Brisbane, Australia, ⁴Immunology Department, Princess Alexandra Hospital, Brisbane- Australia, Brisbane, Australia, ⁵Renal Department, Princess Alexandra Hospital, Brisbane- Australia., Brisbane, Queensland, Australia, ⁶Respiratory Department, Princess Alexandra Hospital, Brisbane- Australia., Brisbane, Queensland, Australia, ⁷Immunopathology Department, Royal Women’s and Children’s Hospital, Brisbane- Australia., Brisbane, Queensland, Australia, ⁸University of Queensland Diamantina Institute and Rheumatology Department, Princess Alexandra Hospital, Brisbane – Australia., Brisbane, Australia
Background/Purpose: In Myeloperoxidase (MPO) Anti Neutrophilic Cytoplasmic Antibody (ANCA)-Associated Vasculitis (MPO-AAV), murine and human studies suggest that the MPO435-465 region, which includes ANCA-binding MPO447-459, the…
Abstract Number: 972 • 2019 ACR/ARP Annual Meeting
Disease Severity Is Linked to an Increase in Autoantibody Diversity in IgG4-related Disease
Hang Liu¹, Cory Perugino ², Musie Ghebremichael ¹, Zachary Wallace ², Sydney Montesi ³, John Stone ⁴ and Shiv Pillai ⁵, ¹Ragon Institute of MGH, MTI and Harvard, Cambridge, ²Massachusetts General Hospital, Boston, ³Massachusetts General Hospital, Boston, MA, ⁴Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ⁵Ragon Institude of MGH, MIT and Harvard, Charlestown, MA
Background/Purpose: The oligoclonal expansion in IgG4-related disease (IgG4-RD) of both plasmablasts and tissue-infiltrating CD4+ cytotoxic T lymphocytes, the identification of specific auto-antigens as B cell…
Abstract Number: 2429 • 2019 ACR/ARP Annual Meeting
Zipcode-Binding Protein 1 (ZBP1) Facilitates Ro60 Surface Translocation, Cellular Growth and Autoimmune Sequelae
Francis DiDonato¹, Jill Buyon ¹ and Robert Clancy ¹, ¹NYU School of Medicine, New York
Background/Purpose: Despite the strong association of maternal anti-Ro60 autoantibodies in the development of SS, Neonatal Lupus (NL) and scLE, understanding causality is challenging given that…
Abstract Number: 4 • 2018 ACR/ARHP Annual Meeting
Anti-Jo1 Positive Myositis Patients Display a Characteristic IgG Fc-Glycan Profile Which Is Further Enhanced in Anti-Jo1 Autoantibodies
Catia Fernandes-Cerqueira^1,2, Nuria Renard^1,2, Antonella Notarnicola^1,2, Edvard Wigren^1,2,3, Susanne Graslund^1,2,3, Roman Zubarev⁴, Ingrid E. Lundberg^1,2 and Susanna L. Lundström⁴, ¹Department of Medicine, Division of Rheumatology, Karolinska Institutet, Stockholm, Sweden, ²Center for Molecular Medicine, Stockholm, Sweden, ³Structural Genomics Consortium, Stockholm, Sweden, ⁴Department of Medical Biochemistry and Biophysics, Division of Physiological Chemistry I, Stockholm, Sweden
Background/Purpose: IgG Fc-glycans affect IgG function and are altered in autoimmune diseases and autoantibodies. Anti-histidyl tRNA synthetase autoantibodies (anti-Jo1) are frequent in myositis associated with…
Abstract Number: 16 • 2018 ACR/ARHP Annual Meeting
Comprehensive Antibody Profiling Using High Density Peptide Arrays Reveals Novel Citrullinated Protein Targets in Rheumatoid Arthritis Serum Samples
Ken Lo¹, Hanying Li², Eric Sullivan² and Jigar Patel², ¹Technology Innovation, Roche Sequencing Solutions - Madison, Madison, WI, ²Roche Sequencing Solutions - Madison, Madison, WI
Background/Purpose: Autoantibodies against citrullinated proteins are found in 64-89% of rheumatoid arthritis (RA) patients, with a specificity of 88-99%. While citrullinated vimentin, fibrin and histone…
Abstract Number: 2010 • 2018 ACR/ARHP Annual Meeting
Anti-Endothelial Cell Antibodies in Pediatric Rheumatic Diseases
Rie Karasawa¹, Toshiko Sato¹, Megumi Tanaka¹, Mayumi Tamaki¹, Kazuo Yudoh¹ and James Jarvis², ¹Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan, ²Pediatrics, University at Buffalo Jacobs School of Medicine & Biomedical Sciences, Buffalo, NY
Background/Purpose: Anti-endothelial cell antibodies (AECA) are antibodies detected in multiple autoimmune and inflammatory diseases. Increased levels of such antibodies may be involved in disease activity…
Abstract Number: 2056 • 2018 ACR/ARHP Annual Meeting
Citrullination Is Not a Determinant in the Lack of Tolerance to Peptidylarginine Deiminase 2 and 4 in Rheumatoid Arthritis
Pooja Naik¹, Ryan Davis², Jon T. Giles³, Felipe Andrade⁴ and Erika Darrah⁵, ¹Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Columbia University, New York, NY, ⁴Medicine/Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Department of Medicine/Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Peptidylarginine deiminase (PAD) 2 and 4 are targets of the humoral response in RA. However, the mechanisms by which these enzymes become immunogenic in…
Abstract Number: 2291 • 2018 ACR/ARHP Annual Meeting
Longitudinal Course of the Disease in Anti-Mi2 Patients: More Intense Muscle Weakness, Good Response to Treatment and Progressive Reduction of Autoantibody Titers
Iago Pinal-Fernandez^1,2, Katherine Pak³, Maria Casal-Dominguez^4,5, Wilson Huang⁴, Jemima Albayda⁶, Eleni Tiniakou⁷, Julie J. Paik¹, Christopher A. Mecoli⁸, Sonye K. Danoff⁹, Lisa Christopher-Stine⁹ and Andrew Mammen^3,10, ¹Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Muscle Diseases Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases. National Institutes of Health, Bethesda, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴NIAMS, NIH, Bethesda, MD, ⁵Johns Hopkins Medical School, Baltimore, MD, ⁶Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁸Internal Medicine/Rheumatology, Johns Hopkins University, Baltimore, MD, ⁹Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁰Center Tower Ste 5300, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Autoantibodies targeting the Mi-2 (Mi-2a and Mi-2b) nuclear antigen in patients with dermatomyositis (DM) were first described in 1985. However, little is known about…
Abstract Number: 26 • 2017 ACR/ARHP Annual Meeting
Single B Cell Analysis Revealed the Relationship Among the Cytokine Profile, Antibody Affinity, and Pathogenic Roles of Autoantigen-Reactive B Cells in Systemic Sclerosis
Takemichi Fukasawa¹, Ayumi Yoshizaki², Satoshi Ebata¹, Kouki Nakamura¹, Ryosuke Saigusa¹, Takashi Yamashita¹, Yoshihide Asano³, Yutaka Kazoe⁴, Kazuma Mawatari⁴, Takehiko Kitamori⁴ and Shinichi Sato⁵, ¹Dermatology, University of Tokyo, Graduate School of Medicine, Tokyo, Japan, ²Department of Dermatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ³Applied Chemistry, University of Tokyo, Graduate School of Medicine, Tokyo, Japan, ⁴Applied Chemistry, University of Tokyo, Graduate School of Engineering, Tokyo, Japan, ⁵Department of Dermatology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Japan
Background/Purpose: Recent studies have indicated that B cells play critical roles in systemic autoimmunity and disease expression through various functions such as induction of the…
Abstract Number: 39 • 2017 ACR/ARHP Annual Meeting
Protein Array Technology Identifies Rituximab-Treated Non-Responder Rheumatoid Arthritis Patients to Generate New Autoantibody Repertoires during Treatment
Zoltán Konthur¹, Melvin Michael Wiemkes², Thomas Häupl², Gerd R. Burmester² and Karl Skriner², ¹Department of Biomolecular Systems, Max Planck Institute of Colloids and Interfaces, Potsdam, Germany, ²Department of Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany
Background/Purpose: Rituximab (RTX) has shown clinical efficacy but up to 40 % of RTX treated rheumatoid arthritis (RA) patients are poor responders (Ann-Rheum-Dis. 2005 Feb;64(2):246-52)…
Abstract Number: 44 • 2017 ACR/ARHP Annual Meeting
Characterization of Novel Stromal-Derived Autoantigens Recognized By RA Synovial Monoclonal Antibodies
Elisa Corsiero¹, Lucas Jagemann¹, Costantino Pitzalis² and Michele Bombardieri³, ¹Centre for Experimental Medicine & Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom, ²Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, ³Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom
Background/Purpose: We previously showed that up to 40% of RA synovial recombinant monoclonal antibodies (RA-rmAbs) generated from germinal center-like structure (GC-LS+) RA synovium recognize citrullinated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].